Cellectar Biosciences
CLRB
8 hedge funds and large institutions have $597K invested in Cellectar Biosciences in 2017 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 3 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
11% less funds holding
Funds holding: 9 → 8 (-1)
24% less capital invested
Capital invested by funds: $782K → $597K (-$185K)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$65.8K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$60.3K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
+$27.4K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$5.48K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$43K |
| 2 |
AIC
AWM Investment Company
New York
|
-$41K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$29K |
| 4 |
State Street
Boston,
Massachusetts
|
-$21.9K |
| 5 |
Morgan Stanley
New York
|
-$5.48K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $240K | +$65.8K | +12 | +32% |
|
|
VKH
2
Virtu KCG Holdings
New York
| $106K | +$60.3K | +11 | +100% |
|
|
3
State Street
Boston,
Massachusetts
| $89K | -$21.9K | -4 | -18% |
|
|
CAM
4
Cormorant Asset Management
Boston,
Massachusetts
| $87K | – | – | – |
|
5
Northern Trust
Chicago,
Illinois
| $27K | – | – | – |
|
|
ARTA
6
A.R.T. Advisors
New York
| $24K | +$27.4K | +5 | New |
|
|
7
Morgan Stanley
New York
| $16K | -$5.48K | -1 | -25% |
|
|
8
UBS Group
Zurich,
Switzerland
| $4K | +$5.48K | +1 | New |
|
|
WAM
9
Wealthspire Advisors (Maryland)
Potomac,
Maryland
| $2K | – | – | – |
|
10
BlackRock
New York
| $1K | – | – | – |
|
11
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| $1K | – | – | – |
|
|
AIC
12
AWM Investment Company
New York
| – | -$41K | -36 | Closed |
|
|
13
Citadel Advisors
Miami,
Florida
| – | -$43K | -6 | Closed |
|
|
14
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$29K | -4 | Closed |
|
CLRB Hedge Fund Activity: Q2 2017 in Review
8 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q2 2017, worth a combined $597K — down 24% from $782K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CLRB and 2 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 2 added.
The largest buyer was Vanguard Group, adding an estimated $65.8K. The largest seller was Citadel Advisors, exiting entirely with an estimated $43K sold.
- 8 institutional investors held Cellectar Biosciences (CLRB) as of Q2 2017, down from 9 in Q1 2017.
- Funds reported $597K of Cellectar Biosciences stock for Q2 2017, down 24% quarter-over-quarter.
- 2 funds opened new Cellectar Biosciences positions in Q2 2017 and 3 closed out, a net change of -1 holder.
- The largest Cellectar Biosciences buyer in Q2 2017 was Vanguard Group, an estimated $65.8K added.
- The largest Cellectar Biosciences seller in Q2 2017 was Citadel Advisors, an estimated $43K sold.
Based on aggregated 13F filings for Q2 2017.